摘要
Abstract
Objective To explore the effects of bacterial lysate capsules combined with probiotics on Notch signaling pathway indicators,intestinal microbiota,and clinical efficacy in children with allergic asthma(AA).Methods A total of 99 children with AA were selected as research subjects and randomly divided into the Broncho-Vaxom group,probiotic group,or combined group,with 33 cases in each group.On the basis of conventional anti-inflammatory and anti-asthmatic therapies,the three groups were treated with bacterial lysate capsules,Bifidobacterium quadruple live tablets,and bacterial lysate capsules combined with Bifidobacterium quadruple live tablets,respectively,all for 3 consecutive months.The Notch signaling pathway indicators,immunological indicators(interferon-γ[IFN-γ],interleukin-4[IL-4],and total immunoglobulin E[tIgE]),counts of intestinal microbiota colonies,and asthma symptom score before and after treatment;the asthma control level after 3 months of treatment;and incidence of adverse reactions during treatment were compared among the three groups.Results Before treatment,there was no statistically significant difference in the baseline indicators among the three groups(all P>0.05).At 1 month and 3 months after treatment initiation,the relative expression levels of NOTCH1 mRNA and NOTCH4 mRNA,serum levels of IL-4 and tIgE,and daytime and nighttime symptom scores in the three groups showed a trend of the combined group's<the Broncho-Vaxom group's<the probiotic group's(all P<0.05);the serum IFN-γ level in the three groups showed a trend of the combined group's>the Broncho-Vaxom group's>the probiotic group's(all P<0.05).At 3 months after treatment initiation,there was a statistically significant overall difference in the total effective rate of asthma control among the three groups(P<0.05),and the total effective rate of asthma control in the combined group was higher than that in the probiotic group(P<0.05);the counts of intestinal Bifidobacteria and Lactobacilli in the three groups showed a trend of the combined group's>the probiotic group's>the Broncho-Vaxom group's(all P<0.05).There was no statistically significant difference in the total incidence of adverse reactions among the three groups during treatment(P>0.05).Conclusion The combined use of bacterial lysate capsules and probiotics demonstrates superior efficacy over monotherapy in treating pediatric AA,potentially mediated by synergistic downregulation of Notch signaling pathway activity,correction of Th1/Th2 immune imbalance,and improvement in gut microbiota colonization,significantly enhancing clinical outcomes without increasing adverse reactions.关键词
过敏性哮喘/细菌溶解产物胶囊/益生菌/Notch信号通路/肠道菌群/哮喘症状评分Key words
Allergic asthma/Bacterial lysate capsules/Probiotics/Notch signaling pathway/Intestinal microbiota/Asthma symptom score分类
医药卫生
